Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Tijdschr Psychiatr ; 65(10): 609-612, 2023.
Artículo en Holandés | MEDLINE | ID: mdl-38174394

RESUMEN

BACKGROUND: Substance use disorders (SUD) are among the most prevalent psychiatric disorders, with high illness costs. A disturbed balance between frontostriatal and stress brain circuitry influences the development of SUD, its continuation, and vulnerability for relapse. AIM: To provide a concise overview of neural networks in SUD, and discuss implications for clinical practice. METHOD: Narrative literature review on neurobiological mechanisms of neural networks in substance use disorders. RESULTS: Changes in frontostriatal circuitry play an important role for sensitivity to substance-related rewards, and can lead to loss of control over substance use. On the other hand, the use of substances affects the brain’s stress system, which affects frontostriatal network functioning. Substance use can activate stress circuitry in the brain, which can lead to an increase in use or relapse. The level at which neural network functioning is affected can differ highly between persons with SUD, and is dependent on the SUD stage and the presence of other psychiatric comorbidity. CONCLUSION: Improved understanding of neural networks involved in SUD can lead to the development of new and more personalized treatment- and prevention strategies. Insights in neural networks also provide a transdiagnostic view from which to understand the phenomenological overlap between psychiatric disorders and frequent comorbidity.


Asunto(s)
Conducta Adictiva , Trastornos Relacionados con Sustancias , Humanos , Trastornos Relacionados con Sustancias/epidemiología , Comorbilidad , Encéfalo , Recurrencia
2.
Tijdschr Psychiatr ; 63(6): 432-440, 2021.
Artículo en Holandés | MEDLINE | ID: mdl-34231862

RESUMEN

BACKGROUND: Prader-Willi syndrome (PWS) is a genetic syndrome characterized by dysmorphic features and endocrine, cognitive and psychiatric problems. Psychiatric problems interfere with the transition from pediatric to adult care. Psychiatric expertise is needed to facilitate this transition. AIM: To provide a literature review on the prevalence and clinical presentation of psychiatric disorders in adults with PWS. METHOD: A systematic literature review following the PRISMA-guidelines. RESULTS: Thirty-three articles were included. Most adults with PWS had a specific behavioral profile with disruptive, autistic and compulsive characteristics. Psychotic symptoms occured in one third of adults with PWS, mostly in patients with maternal uniparental disomy. Mood disorders were present in 10 to 20% of adults with PWS and often accompanied by psychotic features. Studies were limited and heterogeneous in samples and methods. CONCLUSION: There is a broad spectrum of psychiatric symptoms in adults with PWS. The clinical presentation does not fully fit within the DSM categories and shows differences between genetic subgroups. Longitudinal studies assessing the psychiatric symptoms with standardized methods are needed to improve practices on diagnosing, prevention, and treatment.


Asunto(s)
Síndrome de Prader-Willi , Trastornos Psicóticos , Transición a la Atención de Adultos , Adulto , Niño , Humanos , Estudios Longitudinales , Síndrome de Prader-Willi/diagnóstico , Síndrome de Prader-Willi/epidemiología , Síndrome de Prader-Willi/genética
3.
Tijdschr Psychiatr ; 63(5): 324-330, 2021.
Artículo en Holandés | MEDLINE | ID: mdl-34043219

RESUMEN

BACKGROUND: In the coming years, mental health care may come into contact with patients who developed psychological complaints related to their critical illness and stay in the intensive care unit (ICU) as a result of COVID-19. However, the experiences of these patients are to date rarely documented. AIM: Gaining insight into the experiences of COVID-ICU-survivors. METHODS 19 COVID-ICU survivors answered a written survey four months after admission. Screening lists measured psychological complaints and sleeping disorders. Visual analogue scales (VAS) measured the influence of the pandemic context and the quality of life. A written survey mapped patient experiences. Quantitative data were analyzed descriptively and qualitative data by means of thematic analysis. RESULTS: 50% of the participants experienced psychological complaints or sleeping disorders. A limited social network and media coverage of COVID-19 complicated the recovery process of patients. 19% of the participants experienced a reduced quality of life. A weak social network caused feelings of hopelessness. Still, patients showed great resilience. CONCLUSION: Most COVID-ICU survivors are resilient enough to integrate their experiences into their lives, despite the challenges the pandemic context poses on their rehabilitation. It is therefore important not to overmedicalise psychological complaints that occur during rehabilitation. Our attention needs to be directed to those with a weak social network.


Asunto(s)
COVID-19/terapia , Calidad de Vida/psicología , Sobrevivientes/psicología , COVID-19/psicología , Humanos , Unidades de Cuidados Intensivos , Salud Mental , Respiración Artificial , SARS-CoV-2 , Resultado del Tratamiento
4.
Tijdschr Psychiatr ; 63(12): 868-874, 2021.
Artículo en Holandés | MEDLINE | ID: mdl-34978058

RESUMEN

BACKGROUND: Substance use disorder (SUD) is common among youths with attention-deficit/hyperactivity disorder (ADHD). Co-morbid ADHD and SUD in youths complicates screening, diagnosis, and treatment of both disorders and is associated with worse treatment prognosis. Limited research in youths with SUD and co-morbid ADHD provides insufficient basis for firm recommendations. To offer clinicians some guidance on this topic, we present the results of an international consensus procedure. AIM: To summarize an international consensus on diagnosis and treatment of young people with comorbid ADHD and SUD. METHOD: In a modified Delphi-study, a multidisciplinary, international group of 55 experts strived to reach consensus on 37 recommendations. RESULTS: Consensus was reached on 36 recommendations. Routine screening of ADHD and/or SUD is important. For the treatment of co-morbid SUD and ADHD in youths, both psychosocial and pharmacological treatment should be considered. Psychosocial treatment should preferably consist of psychoeducation, motivational interviewing (MI), and cognitive behavioral therapy (CBT) focused on SUD or both disorders. Long-acting stimulants are recommended as first choice pharmacotherapy, preferably embedded in psychosocial treatment. Experts did not agree on the precondition that patients need to be abstinent before starting stimulant treatment. CONCLUSION: Clinicians and youths with co-morbid SUD and ADHD can use this international consensus to choose the best possible treatment.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Estimulantes del Sistema Nervioso Central , Trastornos Relacionados con Sustancias , Adolescente , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Trastorno por Déficit de Atención con Hiperactividad/terapia , Estimulantes del Sistema Nervioso Central/uso terapéutico , Comorbilidad , Consenso , Humanos , Trastornos Relacionados con Sustancias/diagnóstico , Trastornos Relacionados con Sustancias/epidemiología , Trastornos Relacionados con Sustancias/terapia
6.
Tijdschr Psychiatr ; 61(9): 649-653, 2019.
Artículo en Holandés | MEDLINE | ID: mdl-31560785

RESUMEN

A 19-year-old female was seen at the emergency department following an auto-intoxication. An oculogyric crisis (ogc) was observed, in the absence of other extrapyramidal symptoms (eps). In a second anamnesis, patient indicated that she had taken risperidone 3 mg (an atypical antipsychotic). This particular case description of an isolated ogc shows that care providers should be attentive to the occurrence of ogc, even if the most frequent eps are absent. This case also emphasizes the importance of a complete history in order to efficiently and timely guide the care provider to the correct diagnosis.


Asunto(s)
Antipsicóticos/efectos adversos , Distonía/inducido químicamente , Trastornos de la Motilidad Ocular/inducido químicamente , Risperidona/efectos adversos , Diagnóstico Diferencial , Distonía/diagnóstico , Femenino , Humanos , Trastornos de la Motilidad Ocular/diagnóstico , Trastornos Psicóticos/tratamiento farmacológico , Adulto Joven
7.
Tijdschr Psychiatr ; 61(7): 477-487, 2019.
Artículo en Holandés | MEDLINE | ID: mdl-31372969

RESUMEN

BACKGROUND: Substance use disorders (SUD) and attention-deficit/hyperactivity disorder (ADHD) often co-occur in adults. Together, they complicate diagnosis and can negatively influence treatment outcome.
AIM: To develop a practical guide to assist professionals with the screening, diagnosis and treatment of adult patients with SUD and ADHD.
METHOD: A literature search and a consensus procedure between several international scientific and clinical experts. This manuscript is an adapted and summarized Dutch version of the International consensus statement on screening, diagnosis and treatment of patients with SUD and comorbid ADHD.
RESULTS: The routine use of adequate screening tools enables ADHD to be detected earlier in adults with SUD. The diagnostic process for ADHD should be initiated as soon as possible in patients with SUD. Integrated treatment, involving a combination of pharmacotherapy and psychotherapy, is preferred. Long-acting stimulants with up-titration to higher dosages may be considered.
CONCLUSION: Early detection of ADHD in patients with SUD is essential for adequate diagnosis and more effective treatment and follow-up for these patients.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Trastorno por Déficit de Atención con Hiperactividad/terapia , Trastornos Relacionados con Sustancias/diagnóstico , Trastornos Relacionados con Sustancias/terapia , Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Comorbilidad , Consenso , Humanos , Tamizaje Masivo , Trastornos Relacionados con Sustancias/epidemiología
8.
Alcohol Alcohol ; 50(2): 164-72, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25557607

RESUMEN

In Europe between 30 and 50% of all liver transplantations (LTX) are done within the context of chronic end-stage alcoholic liver disease (ALD). However, post-operatively 20-25% of these patients lapse or relapse into heavy alcohol use. Thus, assessment of alcohol relapse risk before enlisting and therapeutic follow-up during and after LTX is of utmost importance. However, as yet there are enormous differences between European countries and between transplant centers, with regard to the assessment methods and criteria and the implementation of therapeutic follow-up. Only the so-called '6-month abstinence' rule is widely used. However, there are not much scientific data validating its use in predicting relapse. Thus, there is a clear need of a more homogeneous approach, which was the focus of a symposium of the European Federation of Addiction Societies during the 14th conference of the European Society for Biomedical Research on Alcoholism, 2013 (ESBRA), entitled 'Liver transplantation: A European perspective'. In a follow-up on this symposium, the authors aim to sum up the evidence of psychiatric assessment criteria and psychiatric treatment interventions relevant in the context of patient selection and patient follow-up within ALD transplantation procedures. Based upon these findings, we propose elements of a procedure that can serve as a first step toward a model of good practice regarding addiction-specialist input within the pre- and post-transplantation period.


Asunto(s)
Alcoholismo/prevención & control , Enfermedad Hepática en Estado Terminal/cirugía , Hepatopatías Alcohólicas/cirugía , Trasplante de Hígado , Alcoholismo/complicaciones , Alcoholismo/terapia , Enfermedad Hepática en Estado Terminal/etiología , Humanos , Hepatopatías Alcohólicas/etiología , Selección de Paciente , Recurrencia , Medición de Riesgo , Factores de Riesgo
9.
Tijdschr Psychiatr ; 55(11): 861-6, 2013.
Artículo en Holandés | MEDLINE | ID: mdl-24242145

RESUMEN

BACKGROUND: ADHD is an important risk factor for the development of substance use disorders (SUD). AIM: To provide an overview of recent Dutch research into the prevalence of ADHD in SUD populations and the neurobiological substrate of the reduced effect of pharmacological treatment of this patient group. METHOD: We describe three studies: a meta-analysis and meta-regression analysis of the prevalence of ADHD in 6689 SUD patients; a cross-sectional study of the prevalence of ADHD and several other psychiatric disorders in 193 methadon maintenance patients, and finally a study in which the availability and occupation of dopamine transporters before and after methylphenidate treatment were measured using SPECT scans in 24 ADHD patients with and without cocaine addiction. RESULTS: The prevalence of ADHD in SUD patients is estimated to be 23.1% (95% confidence interval 19.4-27.2). This prevalence is influenced by the diagnostic instrument for ADHD and by the substance of abuse: cocaine is associated with a lower ADHD prevalence than other substances. The prevalence found among methadone maintenance patients was similar, namely 24.9%; additional comorbid psychiatric disorders were also frequently present. In the imaging study, lower availability of dopamine transporters and lower occupation by methylphenidate were found in cocaine-dependent ADHD patients than in ADHD patients without SUD. CONCLUSION: These studies confirm the high prevalence of ADHD in SUD patients, and provide a possible explanation for the reduced efficacy of methylphenidate in this patient population.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Trastornos Relacionados con Sustancias/epidemiología , Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Estimulantes del Sistema Nervioso Central/uso terapéutico , Comorbilidad , Humanos , Metilfenidato/uso terapéutico , Factores de Riesgo , Trastornos Relacionados con Sustancias/tratamiento farmacológico , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA